Nabi-HB Market Report 2026

Nabi-HB Market Overview

• The Nabi-HB market growth in the historic period has been driven by global hepatitis b prevalence, established use of immune globulins in prophylaxis • Market expansion is supported by expansion of hepatitis prevention initiatives, rising focus on high-risk population protection • Growth Driver: Increasing Prevalence Of Hepatitis B Driving Market Growth Due To Rising Demand For Hepatitis B Immunoglobulin Treatments • North America was the largest region in 2025.

What Is Covered Under Nabi-HB Market?

Nabi-HB is a human hepatitis B immune globulin (HBIG) used for post-exposure prophylaxis of hepatitis B virus (HBV) infection, particularly in individuals who have been exposed to the virus through needlesticks, surgery, or other forms of contact. It provides passive immunity by supplying antibodies against the HBV, offering temporary protection against infection until the body produces its own immune response. The main types of indications for nabi-hb include post-exposure prophylaxis and prevention in high-risk populations. Post-exposure prophylaxis refers to the administration of preventive treatment after potential exposure to a disease, such as hepatitis B, to reduce the likelihood of infection. It is available as an injectable solution and pre-filled syringes and is distributed through hospitals, specialty clinics, public health agencies, and pharmacies. It is used by infants and adult patients.

What Is The Nabi-HB Market Growth Forecast?

The growth in the forecast period can be attributed to expansion of hepatitis prevention initiatives, rising focus on high-risk population protection, increasing demand for emergency immunoprophylaxis, advancements in plasma purification methods, growing public health preparedness efforts. Major trends in the forecast period include increasing demand for passive immunization therapies, rising use of hbig in post-exposure prophylaxis, growing focus on infection prevention strategies, expansion of plasma-derived therapeutics, enhanced emphasis on rapid immune protection.

Global Nabi-HB Market Segmentation

1) By Indication: Post-Exposure Prophylaxis, Prevention in High-Risk Populations 2) By Formulation: Injectable Solution, Pre-Filled Syringes 3) By Distribution Channel: Hospitals, Specialty Clinics, Public Health Agencies, Pharmacies 4) By End User Patients: Infants, Adult Patients

What Are The Drivers Of The Nabi-HB Market?

The increasing prevalence of hepatitis B is expected to propel the growth of the nabi-hb market going forward. Hepatitis B is a serious liver infection caused by the hepatitis B virus (HBV), which can lead to chronic liver diseases and liver cancer. Hepatitis B cases are rising due to factors such as insufficient vaccination coverage, increased unprotected sexual activity, sharing of needles among drug users, and inadequate access to healthcare in high-risk regions. Nabi-HB plays a crucial role in providing immediate, short-term protection against hepatitis B, especially in high-risk scenarios such as post-exposure prophylaxis and during liver transplants. For instance in August 2025 accroding to the The Centers for Disease Control and Prevention a US-based Government agency in 2023, people aged 40–59 years accounted for 48% of all acute hepatitis B cases. Therefore, the increasing prevalence of hepatitis B is driving the growth of the nabi-hb industry. The rise in chronic diseases is expected to propel the growth of the nabi-hb market going forward. Chronic diseases are long-term medical conditions that typically require ongoing management, including treatment and preventive care. Chronic diseases are rising due to factors such as aging populations, unhealthy lifestyles (including poor diet, lack of physical activity, and smoking), environmental factors, and increased exposure to risk factors like pollution and stress. Nabi-HB helps chronic diseases by providing passive immunity against hepatitis B virus (HBV), particularly in individuals who are at high risk of exposure, thereby preventing the development of chronic HBV infection and its long-term complications such as liver cirrhosis or liver cancer, which are common among those with chronic viral infections. For instance, in April 2025, according to Centers for Disease Control and Prevention, a US-based public health agency, 76.4 percent of US adults, representing 194 million people, reported one or more chronic conditions in 2023, including 59.5 percent, 78.4 percent, and 93.0 percent of young, midlife, and older adults, respectively. Therefore, the rise in chronic diseases is a key driver of the nabi-hb industry. The rise in the aging population is expected to propel the growth of the nabi-hb market going forward. An aging population refers to a demographic trend where the proportion of individuals aged 65 and older increases within a population, often due to longer life expectancy and lower birth rates. The aging population is rising due to advancements in healthcare, improved living standards, and increased life expectancy, coupled with declining birth rates. Nabi-HB helps the aging population by providing passive immunity against the hepatitis B virus, reducing the risk of chronic infections and their complications, which are more prevalent in older adults due to weakened immune systems and increased exposure to viral infections, ultimately supporting healthier aging and reducing long-term healthcare costs. For instance, in July 2024, according to the UK Parliament's House of Commons Library, a UK-based government administration, in 2022, there were 12.7 million people aged 65 or older in the UK, representing 19% of the total population. This number is projected to rise to 22.1 million by 2072, accounting for 27% of the population. Therefore, the rise in the aging population is driving the growth of the nabi-hb industry.

Key Players In The Global Nabi-HB Market

Major companies operating in the nabi-hb market are ADMA Biologics Inc.

Regional Insights

North America was the largest region in the nabi-hb market in 2025. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Nabi-HB Market?

The nabi-hb market consists of sales of combination vaccines, immunoglobulins, flu vaccines and pneumococcal vaccines. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Nabi-HB Market Report 2026?

The nabi-hb market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the nabi-hb industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.